The Effects and Safety of Chinese Oral Herbal Paste on Stable Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Journal
Evidence-based complementary and alternative medicine : eCAM
ISSN: 1741-427X
Titre abrégé: Evid Based Complement Alternat Med
Pays: United States
ID NLM: 101215021
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
09
2019
revised:
14
01
2020
accepted:
28
01
2020
entrez:
21
4
2020
pubmed:
21
4
2020
medline:
21
4
2020
Statut:
epublish
Résumé
Chinese oral herbal paste has been widely used in the treatment of chronic obstructive pulmonary disease (COPD). However, the treatment effects of herbal paste were controversial and lack evidence to support its clinical use. This study aims to systematically assess the efficacy and safety of Chinese oral herbal paste for the treatment of stable COPD. PubMed, Web of Science, CENTRAL, EMBASE, CNKI, VIP, CBM, and WANFANG database in addition to two websites of clinical trial registry were searched from respective inception to August 2019. Only randomized controlled trials (RCTs) studying Chinese herbal paste for the treatment of stable COPD were included. Methodological quality was assessed based on Cochrane risk of bias and GRADE approach. Data were analyzed using RevMan 5.3. A total of 19 RCTs with 1303 individuals compared Chinese oral herbal paste and Western medicine (WM) with WM alone were included for meta-analysis. The review showed compared with WM alone, the combination of herbal paste and WM reduced exacerbation frequency. Subgroup analyses showed that after two to three months of treatment, compared with WM alone, Chinese herbal paste plus WM significantly decreased the St George's Respiratory Questionnaire (SGRQ) scores, COPD assessment test (CAT) scores, and scores of traditional Chinese medicine (TCM) syndrome, and improved clinical effective rates, lung function, and 6-minute walk distance. No serious adverse events related to herbal paste were reported. Current evidence showed that Chinese oral herbal paste may be an effective and well-tolerated adjuvant therapy for stable COPD. Considering the risks of bias and heterogeneity, more high-quality, well-designed RCTs are still needed.
Sections du résumé
BACKGROUND
BACKGROUND
Chinese oral herbal paste has been widely used in the treatment of chronic obstructive pulmonary disease (COPD). However, the treatment effects of herbal paste were controversial and lack evidence to support its clinical use. This study aims to systematically assess the efficacy and safety of Chinese oral herbal paste for the treatment of stable COPD.
METHODS
METHODS
PubMed, Web of Science, CENTRAL, EMBASE, CNKI, VIP, CBM, and WANFANG database in addition to two websites of clinical trial registry were searched from respective inception to August 2019. Only randomized controlled trials (RCTs) studying Chinese herbal paste for the treatment of stable COPD were included. Methodological quality was assessed based on Cochrane risk of bias and GRADE approach. Data were analyzed using RevMan 5.3.
RESULTS
RESULTS
A total of 19 RCTs with 1303 individuals compared Chinese oral herbal paste and Western medicine (WM) with WM alone were included for meta-analysis. The review showed compared with WM alone, the combination of herbal paste and WM reduced exacerbation frequency. Subgroup analyses showed that after two to three months of treatment, compared with WM alone, Chinese herbal paste plus WM significantly decreased the St George's Respiratory Questionnaire (SGRQ) scores, COPD assessment test (CAT) scores, and scores of traditional Chinese medicine (TCM) syndrome, and improved clinical effective rates, lung function, and 6-minute walk distance. No serious adverse events related to herbal paste were reported.
CONCLUSION
CONCLUSIONS
Current evidence showed that Chinese oral herbal paste may be an effective and well-tolerated adjuvant therapy for stable COPD. Considering the risks of bias and heterogeneity, more high-quality, well-designed RCTs are still needed.
Identifiants
pubmed: 32308709
doi: 10.1155/2020/5867086
pmc: PMC7086443
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
5867086Informations de copyright
Copyright © 2020 Yan Zeng et al.
Déclaration de conflit d'intérêts
All authors have no conflicts of interest to declare.
Références
Lancet Respir Med. 2016 Jun;4(6):473-526
pubmed: 27185520
J Aerosol Med Pulm Drug Deliv. 2010 Oct;23(5):323-8
pubmed: 20804428
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
Int J Chron Obstruct Pulmon Dis. 2018 Jul 30;13:2301-2311
pubmed: 30104870
Respir Med. 2011 Jun;105(6):930-8
pubmed: 21367593
Respir Res. 2014 Oct 21;15:122
pubmed: 25331383
Lancet. 2011 Sep 10;378(9795):1027-37
pubmed: 21907866
Eur Respir J. 2012 Jan;39(1):38-45
pubmed: 21737561
Cochrane Database Syst Rev. 2018 Dec 11;12:CD011594
pubmed: 30536566
Ther Adv Chronic Dis. 2014 Sep;5(5):212-27
pubmed: 25177479
Cochrane Database Syst Rev. 2016 Jun 06;(6):CD008532
pubmed: 27271056
Medicine (Baltimore). 2019 Jul;98(28):e16444
pubmed: 31305473
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
Explore (NY). 2006 Mar;2(2):143-9
pubmed: 16781628
Lancet Respir Med. 2014 Mar;2(3):195-203
pubmed: 24621681
COPD. 2007 Sep;4(3):191-4
pubmed: 17729062
Int J Chron Obstruct Pulmon Dis. 2018 Apr 27;13:1353-1364
pubmed: 29731623
Lancet. 2018 Apr 28;391(10131):1706-1717
pubmed: 29650248
Am J Respir Crit Care Med. 2013 Feb 15;187(4):382-6
pubmed: 23262518
Am J Respir Crit Care Med. 2017 May 15;195(10):1333-1343
pubmed: 27409253
Thorax. 2017 Oct;72(10):919-927
pubmed: 28432209
Cochrane Database Syst Rev. 2019 Mar 06;3:CD012930
pubmed: 30839102
Obstet Gynecol. 2010 May;115(5):1063-70
pubmed: 20410783
Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418-22
pubmed: 9603117
PLoS One. 2019 May 23;14(5):e0217143
pubmed: 31120946
Am J Respir Crit Care Med. 2002 Mar 1;165(5):704-7
pubmed: 11874818